Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia

Patients with relapsed chronic lymphocytic leukemia (CLL) and high-risk features, such as fludarabine refractoriness, complex karyotype, or abnormalities of chromosome 17p, experience poor outcomes after standard fludaradine-based regimens. Alemtuzumab is a chimeric CD52 monoclonal antibody with act...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Badoux, Xavier C., Keating, Michael J., Wang, Xuemei, O'Brien, Susan M., Ferrajoli, Alessandra, Faderl, Stefan, Burger, Jan, Koller, Charles, Lerner, Susan, Kantarjian, Hagop, Wierda, William G.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2011
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123326/
https://ncbi.nlm.nih.gov/pubmed/21670470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-03-341032
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars